BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hesselmann, S
Right arrow Articles by Willich, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hesselmann, S
Right arrow Articles by Willich, N
British Journal of Radiology 75 (2002),180-184 © 2002 The British Institute of Radiology

Case report

Kasabach–Merritt syndrome: a review of the therapeutic options and a case report of successful treatment with radiotherapy and interferon alpha

S Hesselmann, MD1, O Micke, MD1, T Marquardt, MD2, S Baas, MD2, J H Bramswig, MD2, E Harms, MD2 and N Willich, MD1

Departments of 1Radiotherapy and 2Pediatrics, University Hospital Muenster, Albert-Schweitzer-Straße 33, D-48149 Muenster, Germany

We describe the successful treatment of a neonate with Kasabach–Merritt syndrome who received local irradiation and interferon alpha therapy after failure of corticosteroid treatment. A male neonate, born after an uneventful pregnancy, had a huge haemangioma involving the upper right cervical region as well as severe thrombocytopenia. He was treated with corticosteroids, interferon alpha and radiotherapy. Prednisolone therapy (5 mg kg-1 day-1) was started at 41 days of age. No therapeutic effect was observed after 2 weeks. At this time the tumour size had increased dramatically, platelet counts had decreased progressively and coagulation abnormalities had developed. Because corticosteroid therapy had been ineffective and the child was in a life-threatening condition, irradiation was delivered up to a total dose of 9.5 Gy in five fractions. Simultaneously, prednisolone therapy was slowly decreased and interferon alpha therapy (3 million U m-2 day-1) was started and continued for 6 weeks. After irradiation with 9.5 Gy and beginning interferon alpha therapy, the tumour decreased in size and coagulation parameters normalized within 4 weeks. 6 months later, platelet counts and coagulation parameters were still normal. The tumour had further decreased in size. No acute severe side effects were observed. Radiation therapy combined with interferon alpha treatment is an alternative treatment modality when high dose corticoid steroid therapy has been ineffective in patients with Kasabach–Merritt syndrome, despite the risks of growth delay and secondary malignancy. In children showing no response to corticosteroids, radiotherapy and/or interferon alpha should be considered in Kasabach–Merritt syndrome.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2002 by the British Institute of Radiology.